Market Access News | pharmaphorum

News

Regeneron set for August FDA decision on BCMA bispecific

Regeneron’s bid to join the market for BCMA-targeted bispecific antibodies for multiple myeloma is nearing a conclusion, with the FDA starting a priority review of its lin

News

Pfizer’s Litfulo becomes first NHS drug for alopecia areata

Pfizer’s JAK/TEC inhibitor Litfulo has been recommended for NHS use as a treatment for hair loss caused by severe alopecia areata, the first drug therapy for a condition t

News

United sues FDA to try to block rival’s drug application

In an unusual move, United Therapeutics has filed a lawsuit against the FDA that claims the regulator is sidestepping established norms in allowing rival Liquidia to file

News

US, EU regulators start swift reviews of Servier glioma drug

The US FDA and EMA in the EU have started accelerated reviews of Servier’s vorasidenib for IDH-mutated low-grade glioma, which is vying to become the first targeted therapy for this a

News

FDA starts review of Argenx drug in rare disease CIDP

The US FDA has said it plans to deliver a decision in June on the use of Argenx’ Vyvgart Hytrulo in chronic inflammatory demyelinating polyneuropathy (CIDP), as the compan

News

Pfizer’s ulcerative colitis drug Velsipity gets EU okay

The European Commission has approved Pfizer’s S1P receptor modulator Velsipity as a treatment for ulcerative colitis (UC), raising the pressure on Bristol-Myers Squibb’s f

Regeneron set for August FDA decision on BCMA bispecific

Pfizer’s Litfulo becomes first NHS drug for alopecia areata

United sues FDA to try to block rival’s drug application

US, EU regulators start swift reviews of Servier glioma drug

FDA starts review of Argenx drug in rare disease CIDP

Pfizer’s ulcerative colitis drug Velsipity gets EU okay

Bankruptcy threat looms as Quince runs out of options

How to meet your physicians where they are online

News

Editor's Picks